Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 163

Results For "NCEs"

2293 News Found

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US
News | August 31, 2022

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US


Thermo Fisher Scientific present new innovations to improve biopharmaceutical and proteomics workflows
News | August 30, 2022

Thermo Fisher Scientific present new innovations to improve biopharmaceutical and proteomics workflows

New mass spectrometry instrument and consumables launch during IMSC 2022


KIMS Hospitals to acquire majority stake in Kingsway Hospitals, Nagpur
Healthcare | August 30, 2022

KIMS Hospitals to acquire majority stake in Kingsway Hospitals, Nagpur

The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.


Philips spotlights integrated, data-driven cardiology solutions at ESC 2022
Digitisation | August 28, 2022

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022

Philips AI-powered interventional and diagnostic smart systems enhances diagnostic confidence, drive greater efficiency, and improve patient outcomes


Qdenga approved in Indonesia for use regardless of prior dengue exposure
Drug Approval | August 28, 2022

Qdenga approved in Indonesia for use regardless of prior dengue exposure

Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age


10th Merck Bioforum India 2022 on Sept. 6-8
News | August 26, 2022

10th Merck Bioforum India 2022 on Sept. 6-8

This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape


Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer
Drug Approval | August 26, 2022

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients


Lonza introduces X-ray powder diffraction at Monteggio
News | August 23, 2022

Lonza introduces X-ray powder diffraction at Monteggio

This rapid analytical technique provides additional information about the polymorph and solid-state properties of active pharmaceutical ingredients (APIs)


8th edition of Indo-Japanese Chronic Total Occlusion (IJCTO) summit concluded successfully
News | August 22, 2022

8th edition of Indo-Japanese Chronic Total Occlusion (IJCTO) summit concluded successfully

The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO